[go: up one dir, main page]

WO2014077437A1 - Composition contenant de l'extrait de semen pharbitidis utilisable pour traiter le cancer du rein et en tant qu'aliment fonctionnel - Google Patents

Composition contenant de l'extrait de semen pharbitidis utilisable pour traiter le cancer du rein et en tant qu'aliment fonctionnel Download PDF

Info

Publication number
WO2014077437A1
WO2014077437A1 PCT/KR2012/009744 KR2012009744W WO2014077437A1 WO 2014077437 A1 WO2014077437 A1 WO 2014077437A1 KR 2012009744 W KR2012009744 W KR 2012009744W WO 2014077437 A1 WO2014077437 A1 WO 2014077437A1
Authority
WO
WIPO (PCT)
Prior art keywords
kidney cancer
extract
black
composition
present
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/KR2012/009744
Other languages
English (en)
Korean (ko)
Inventor
황성연
정경채
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GYEONGSANGBUK-DO MEDICAL CROP CLUSTER
KOREA BIO MEDICAL SCIENCE INSTITUTE Co Ltd
Original Assignee
GYEONGSANGBUK-DO MEDICAL CROP CLUSTER
KOREA BIO MEDICAL SCIENCE INSTITUTE Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GYEONGSANGBUK-DO MEDICAL CROP CLUSTER, KOREA BIO MEDICAL SCIENCE INSTITUTE Co Ltd filed Critical GYEONGSANGBUK-DO MEDICAL CROP CLUSTER
Priority to PCT/KR2012/009744 priority Critical patent/WO2014077437A1/fr
Publication of WO2014077437A1 publication Critical patent/WO2014077437A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/39—Convolvulaceae (Morning-glory family), e.g. bindweed
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Definitions

  • the present invention relates to a novel use of black shaft extract. Specifically, the present invention relates to a therapeutic composition and a functional food containing a black shaft extract as an active ingredient, which shows an excellent prophylactic or therapeutic effect against kidney cancer.
  • the kidney is an important urinary system that has the role of excreting waste products in vitro by filtering blood to produce urine. At the same time, it is also an important endocrine organ that produces hormones such as angiotensin, which regulates blood pressure, and erythropoietin, a red blood cell hematopoietic factor. Renal tumors include kidney cell cancer in adults, Wilms' tumor in children, and sarcoma as a rare tumor, but the most common malignancy below Renal cell cancer, a tumor, is called kidney cancer. The incidence of renal cancer is about 2.5 per 100,000 population, and male to female ratio is 2 to 3: 1. Among urological malignancies, there are many tumors following prostate cancer and bladder cancer.
  • kidney cancer Genetic factors are also known as risk factors for kidney cancer, but generally include smoking and excessive fat intake. It is also known that the incidence of such tumors is high in patients undergoing long-term dialysis. In kidney cancer, when the tumor has a maximum diameter of 5 cm or less, some subjective symptoms rarely occur and are often found by CT scan or the like at the time of examination. Larger tumors may include hematuria, abdominal tumors, and pain. In addition, systemic symptoms may cause fever, weight loss, anemia and the like, and rarely, endocrine factors may cause erythrocytosis, hypertension, hypercalcemia, and the like.
  • vein veins of the abdominal body surface or venous varicose veins occur due to the progression of kidney cancer into the inferior vena cava.
  • About 20% of kidney cancers are found from lung or bone metastases.
  • tumors tend to spread in veins, and metastasis to other organs is likely to occur.
  • VHL von-Hippel-Lindau
  • the main treatment for kidney cancer is surgical therapy. Regardless of the timing of the disease, extraction of the kidneys or partial extraction of the kidneys is the most common where possible, and even if there is metastasis, surgical removal of the kidneys may be considered.
  • Arterial embolization of the renal artery may be used as a method other than the surgical therapy. This method may be performed prior to surgery in cases where it is impossible to extract or when a large tumor is removed.
  • Recent advances in burn diagnostics have led to early detection of renal cancer, even at very small sizes, resulting in more than 90% healing in early cancer. However, since the therapeutic results of large tumors larger than 5 cm or tumors with metastases are poor (the 5-year survival rate of all renal cell carcinomas is about 50 to 60%), the importance of early detection is recognized.
  • the black shaft (black-haired, Pharbitidis Semen ) refers to the seeds of the morning glory ( Pharbitis nil choisy) (buckthorn and convolvulaceae), which are found in Chinese herbal medicine and folklore. Secret, alluvial abdominal pain, swelling, abdominal bloating, constipation was used. Morning glory is native to tropical Asia such as India and is known to have about 256 varieties. Black seed is also known as black axis ( ⁇ ⁇ ), white seed is white axis ( ⁇ ⁇ ). prohibition( The name ⁇ ) refers to the form of seeds, and the names of sorghum and roast are named after the shape of the petals. Wake up a little smell, irritating, taste bitter, cold and poisonous.
  • the fruit contains two seeds in each of the three chambers of the genus and ripens in September-October.
  • the appearance is divided into 4 ⁇ 6 equal lengths of the beads.
  • the outer surface is black to gray brown or greyish white and smooth or slightly crusted.
  • the outer surface of the seed husk is dense with short hairs, and the bottom of the ridge is closed.
  • Transverse plane fan-shaped, pale yellowish brown to pale grey-brown, and the quality is dense.
  • Seed shell is thin, the outer layer is dark gray, and the inner layer is light gray.
  • Other names are Black Axis, Guicho, White Dog, White Axis, Bunpumcho, Chogeumryeong ⁇ ), black dog ( ⁇ ⁇ ⁇ ), etc., has the effect of nutrition and Bosin.
  • a component called parbitin contained in the hypothalamic-nuts is broken down by the bile sera in the intestine to produce Ipulolic acid. It gives intense stimulation to the intestinal tract, increasing peristalsis in the intestine, causing redness in the intestinal mucosa and increasing secretion. Therefore, when you do not see the stool is firmly effective. This is especially effective when the body's essences do not see dry stools or patients who usually have stools. It is also good for the body as well as the body. Effective for seawater and asthma and used for stubborn constipation and parasite removal. Intestinal interlocking action as a pharmacological action has been reported to have a strong lower action.
  • the black axis contains about 11% of fatty oil and 2% of pharbitin, a resinous glycoside, and is known to have hypothalamic, diuretic and insecticidal effects (KP Part 2 651). It is also effective in improving sea water, asthma and constipation, and is used as a cosmetic composition for massage to remove impurities from the skin. It also works when you don't see diuretics-urine. Especially used for Gochang disease. Can be used when revenge is cold and swelling in the body. Expectant effect on sputum, cough, asthma, etc. It is used as a remedy for insecticidal action-roundworms, tapeworms, etc., and it is used to alleviate various symptoms caused by parasites or abdominal pain.
  • KP Part 2 651 hypothalamic, diuretic and insecticidal effects
  • kidney cancer-related diseases of the axial axis None is disclosed or disclosed in this document in connection with kidney cancer-related diseases of the axial axis.
  • the present inventors completed the present invention by confirming that the black shaft extract can effectively kill kidney cancer cells during the study of herbal medicine for black shaft.
  • the present invention provides a composition for preventing and treating kidney cancer comprising an active ingredient extracted from the black shaft with an organic solvent. It is preferable that the said organic solvent is ethanol.
  • the present invention provides a functional food for preventing kidney cancer containing black ethanol extract containing a food supplement acceptable food additive as an active ingredient.
  • the present invention provides a composition for the prevention and treatment of kidney cancer containing black ethanol extract as an active ingredient.
  • the composition of the present invention comprises a black shaft extract as an active ingredient, and may further include a pharmaceutically acceptable carrier or diluent.
  • the ethanol extract is preferably extracted at 50 ° C. for 24 hours, wherein the ethanol extract is more preferably dried and concentrated at 45 ° C. under reduced pressure, and the ethanol Is most preferably 95%.
  • the kidney cancer is preferably renal cell cancer.
  • the black shaft extract of this invention is possible in any site of black shaft, it is preferable to extract from a root preferably.
  • the extraction solution may be obtained by extraction with water or an organic solvent, and examples of the organic solvent may include lower alcohols, acetone, chloroform, methylene chloride, ether, ethyl acetate, and hexane.
  • Lower alcohols include methanol, ethanol, propanol and butanol, with ethanol being most preferred.
  • the black shaft dry matter or powder 1 to 5 times, preferably 3 times, 95% ethanol is added to the black shaft dry matter or powder and 10 to 100 hours, preferably 15 to 15, at a temperature of 20 to 100 ° C, preferably 40 to 60 ° C. Extraction for 40 hours, more preferably 24 hours and then filtered to produce an ethanol extract of black shaft.
  • the filtrate obtained by filtering the extract may be concentrated under reduced pressure.
  • the extraction process may be repeated two or more times as necessary, and the extract obtained after filtration may be lyophilized or dried under reduced pressure to obtain a powder form.
  • the "pharmaceutically acceptable carrier” is a pharmaceutically acceptable substance such as a liquid or solid filler, diluent, excipient or solvent which serves to transport the active ingredient from one organ or part of the body to another organ or part of the body. , Composition or vehicle.
  • the composition for treating kidney cancer of the present invention may be prepared as a medicament by adding one or more pharmaceutically acceptable carriers together with the active ingredient.
  • the carrier may include, but is not limited to, saline, buffered saline, water, glycerol and ethanol, and any suitable agent known in the art (Remingtons's Pharmaceutical Science (Recent Edition), Mack Publishing Company, Easton PA) may be used. .
  • Formulations for pharmaceutical formulation of the black shaft extract of the present invention can be administered orally during clinical administration and can be used in the form of general pharmaceutical formulations, when formulated, commonly used fillers, extenders, binders, wetting agents, disintegrants, It is prepared using diluents or excipients such as surfactants.
  • Solid preparations for oral administration include tablets, pills, powders, granules, capsules, etc.
  • liquid preparations for oral use include suspensions, solvents, emulsions, and syrups.
  • various excipients may be included, such as wetting sweeteners, fragrances, preservatives and the like.
  • the herbal medicine that may be added to the composition of the present invention may be any pharmaceutically acceptable herbal medicine, for example, Angelica tenuissimae Radix, Gastrodiae Rhizoma, Bapleuri Radix, Angelica ( Angelicae gigantis Radix, Persicae Semen, Cinnamomi Ramulus, Rhubarb (Rhei Rhizoma), Licorice (Glycyrrhizae Radix), Cnidii Rhizoma, Aurantii nobilis Pericarpium, Taxa (Alismatis Rhizoma) Coptidis Rhizoma, Scutellariae Radix, Hoelen, Peeoniae Radix, Atractylodis Rhizoma alba, Phellodendri Cortex, Gardeniae Fructus, Pinelliae Tuber, Ramulu Set (Uncaria) Uncus, Ponciri Fructus, Ginseng, Gingseng, Liriopis Tuber, Poly
  • composition of the present invention may be administered in various parenteral formulations during actual clinical administration, and solid preparations include tablets, pills, powders, granules, capsules, and the like.
  • solid preparations include tablets, pills, powders, granules, capsules, and the like.
  • excipients such as wetting agents, sweeteners, fragrances, and preservatives may be included.
  • preparations for parenteral administration include sterile aqueous solutions, non-aqueous solvents, suspensions, emulsions, lyophilized preparations, suppositories.
  • non-aqueous solvent and the suspension solvent propylene glycol, polyethylene glycol, vegetable oil such as olive oil, injectable ester such as ethyl oleate, and the like can be used.
  • base of the suppository witepsol, macrogol, tween 61, cacao butter, laurin butter, glycerogelatin and the like can be used.
  • calcium or vitamin D 3 may be added to enhance the efficacy of the treatment.
  • Such compositions may be presented in unit-dose (single) or multi-dose (several) containers, such as sealed ampoules and vials, and immediately before use, sterile liquid carriers such as injectable water. Can be stored under freeze-drying conditions requiring only the addition of. Immediate injection solutions and suspensions can be prepared from sterile powders, granules and tablets.
  • the formulations of the present invention can be applied differently depending on the age, sex, condition of the subject, the absorption of the active ingredient in the body, the inactivation rate and excretion rate, the drug used in combination.
  • the invention also includes formulations of dosage units.
  • the formulations are present in individual dosage forms, such as tablets, coated tablets, capsules, pills, suppositories, and ampoules, wherein the amount of active compound in the drug corresponds to the fraction or multiple of the individual dosage.
  • Dosage units may contain, for example, one, two, three or four times the individual dosage, or 1/2, 1/3 or 1/4 times.
  • the individual dosages preferably contain an amount in which the active compound is administered at one time, which usually corresponds to all, 1/2, 1/3 or 1/4 times the daily dosage.
  • extract refers to an active ingredient isolated from natural products.
  • the extract may be obtained by an extraction process using water, an organic solvent, or a mixed solvent thereof, and includes an extract, a dry powder thereof, or any form formulated using the same.
  • ethanol extract of black shaft killed 97.3% of ACHN kidney cancer cells at 100 ⁇ g / ml, and IC 50 (half maximal inhibitory concentration) was 4.4 ⁇ g / ml.
  • IC 50 half maximal inhibitory concentration
  • prevention means any action that inhibits or delays the development of kidney cancer by administration of the composition.
  • treatment means any action that improves or advantageously changes the symptoms of kidney cancer by administration of the composition.
  • the black shaft extract may be extracted and used using water, an organic solvent, or a mixed solvent thereof.
  • it is extracted using an organic solvent, in particular ethanol.
  • the extracted solution can be used directly or can be concentrated and / or dried.
  • methanol, ethanol, isopropanol, butanol, ethylene, acetone, hexane, ether, chloroform, ethyl acetate, butyl acetate, dichloromethane, N, N-dimethylformamide (DMF), dimethyl sulfoxide (DMSO), 1,3-butylene glycol, propylene glycol, or a mixed solvent thereof may be used and extracted by room temperature or warming under conditions where the active ingredient of the herbal medicine is not destroyed or minimized.
  • the degree of extraction and loss of the active ingredient of the drug may vary, so select an appropriate organic solvent.
  • the extraction method is not particularly limited, and examples thereof include cold needle extraction, ultrasonic extraction, reflux cooling extraction, and the like.
  • Filtration is a process of removing the suspended solid particles from the extract, it may be used to filter the particles using cotton, nylon or the like, or may be used, such as ultrafiltration, cryofiltration, centrifugal separation, but is not limited thereto.
  • Concentration of the extract may be used, such as concentrated under reduced pressure, reverse osmosis concentration.
  • the drying step after concentration includes freeze drying, vacuum drying, hot air drying, spray drying, reduced pressure drying, foam drying, high frequency drying, infrared drying, and the like. If desired, a process of grinding the final dried extract may be added.
  • the extract can perform an additional fractionation process.
  • the extract is suspended in distilled water to obtain a nonpolar solvent soluble layer by extraction and separation with a nonpolar organic solvent such as hexane, ether, dichloromethane, chloroform, ethyl acetate, or a mixed solvent thereof. It can be used by concentrating and / or drying it.
  • a nonpolar organic solvent such as hexane, ether, dichloromethane, chloroform, ethyl acetate, or a mixed solvent thereof. It can be used by concentrating and / or drying it.
  • the term "pharmaceutically acceptable salts” means salts derived from pharmacologically or physiologically acceptable inorganic acids, organic acids and bases.
  • suitable acid include hydrochloric acid, bromic acid, sulfuric acid, nitric acid, perchloric acid, fumaric acid, maleic acid, phosphoric acid, glycolic acid, lactic acid, salicylic acid, succinic acid, toluene-p-sulfonic acid, tartaric acid, acetic acid, citric acid, methanesulfonic acid, Formic acid, benzoic acid, malonic acid, naphthalene-2-sulfonic acid, benzenesulfonic acid, and the like.
  • Salts derived from suitable bases may include alkali metals such as sodium, alkaline earth metals such as magnesium, ammonium and the like.
  • the pharmaceutical composition for preventing and treating kidney cancer diseases of the present invention comprises 0.1 to 50% by weight of the extract or compound based on the total weight of the composition.
  • the composition does not increase the efficacy, but may include additional ingredients that are commonly used in the pharmaceutical composition to improve the smell, taste, time and the like.
  • the composition adds inorganic and organic additives such as vitamins B1, B2, B6, C, E, niacin, carnitine, betaine, folate pantothenic acid, biotin, zinc, iron, calcium, chromium, magnesium, and mixtures thereof. It can be included as.
  • the composition may include a substance having a therapeutic activity against kidney cancer used alone or used in the past.
  • the term "patient” refers to humans, horses, sheep, pigs, goats, and camels having a disease caused by kidney cancer and its direct and indirect causes, and whose symptoms may be improved by administering the composition of the present invention.
  • Means animals such as nutrition, dogs.
  • the term "administration” means introducing a predetermined substance into a patient by any suitable method, and the route of administration of the composition of the present invention is oral or parenteral via any general route as long as the target tissue can be reached. May be administered.
  • the composition may be administered by any device in which the active agent may migrate to the target cell.
  • composition of the present invention is administered in a pharmaceutically effective amount.
  • pharmaceutically effective amount means an amount sufficient to treat a disease at a reasonable benefit / risk ratio applicable to medical treatment, and an effective dose level refers to a patient's sexually transmitted disease, age, severity, and drug activity.
  • the compositions of the present invention may be administered as individual therapeutic agents or in combination with other therapeutic agents and may be administered sequentially or simultaneously with conventional therapeutic agents. It may be single or multiple doses.
  • the method of administering the composition comprising the extract or compound prepared according to the preparation method of the present invention is preferably oral administration or intravenous administration.
  • the effective dose is oral administration, it is usually 1 to 1 time per adult. 500 mg / kg is preferred, and in the case of intravenous administration, 1 to 100 mg / kg is preferred, and may be administered 2-3 times a day.
  • Dosage levels for a particular patient may vary depending on gender, age, shrinkage, diet, time of administration, method of administration, drug mixture, the condition of the patient, and the extent of neurological disease.
  • the present invention provides a functional food for preventing kidney cancer containing black ethanol extract containing a food supplement acceptable food additive as an active ingredient.
  • Functional food of the present invention preferably contains 0.1 to 5% by weight, more preferably 1% by weight of the ethanol extract relative to the total weight.
  • Functional food of the present invention is not particularly limited in the formulation, for example, dairy products including meat, sausage, bread, chocolate, candy, snacks, confectionery, pizza, ramen, other noodles, gum, ice cream, Various soups, beverages, tea, drinks, alcoholic beverages and vitamin complexes, etc., and includes all of the health food in the usual sense.
  • “functional food” means a food manufactured and processed using raw materials or ingredients having functional properties useful for the human body according to Act No. 6767 of the Health Functional Food Act, and “functional” refers to the structure of the human body And ingestion for the purpose of obtaining nutrients for function or for obtaining useful effects in health uses such as physiological actions.
  • the black shaft extract of the present invention when the black shaft extract of the present invention was injected into ACHN kidney cancer cells, it was confirmed that ACHN kidney cancer cells were killed (see FIG. 1 ). Therefore, it can be seen that the black shaft extract has a renal cancer treatment effect.
  • the present invention was completed by preparing a functional food for preventing kidney cancer containing black shaft extract as an active ingredient (see Preparation Example 2 ).
  • the black shaft extract of the present invention inhibits the growth of kidney cancer cells and induces apoptosis. Therefore, the composition for treating renal cancer according to the present invention will be very effective in the treatment of renal cancer patients.
  • 1 is a result of Alamar Blue analysis to determine the effect of the introduction of the black axis on the growth of kidney cancer cells in ACHN cells, human kidney cancer cells, wherein the X axis is the concentration of the black axis extract, the Y axis is surviving human kidney cancer cells Survival rate.
  • Example 2 is an EdU assay result to determine whether the introduction of the black axis obtained in Example 1 in the human kidney cancer cell line ACHN cells to stop the cell cycle and inhibit proliferation of kidney cancer cells.
  • Figure 3 compares the activity of c-Myc cell signal in a reporter assay to determine the effect of the introduction of the black axis obtained in Example 1 on the c-Myc cell signal of kidney cancer cells in ACHN cells, a human kidney cancer cell line The result of the analysis.
  • Figure 4 compares the activity of AP-1 cell signal in a reporter assay to determine the effect of the introduction of the black axis obtained in Example 1 on the AP-1 cell signal of kidney cancer cells in ACHN cells, a human kidney cancer cell line The result of the analysis.
  • Figure 5 compares the activity of NF- ⁇ B cell signal in a reporter assay to determine the effect of the introduction of the black axis obtained in Example 1 on the NF- ⁇ B cell signal of kidney cancer cells in ACHN cells, a human kidney cancer cell line The result of the analysis.
  • Figure 6 shows the effect of the introduction of the black axis obtained in Example 1 on the major cell signal that promotes the proliferation of kidney cancer cells in ACHN cells, a human kidney cancer cell line p-ERK, Ras, ⁇ - This is the result of quantitative changes such as actin protein.
  • ACHN cells which are human kidney cancer cells
  • Alamar Blue assay is a modified form of the MTT assay, in which a specific enzyme degrades a living cell and then measures the fluorescence intensity of the product as the compound breaks down to determine the relative number of living cells after treatment. I am an experimental method. It will be described in more detail below.
  • ACHN cells a kidney cancer cell line used in the present invention, were distributed from Korean Cell Line Bank (KCLB) and used for experiments. Specifically, ACHN kidney cancer cells (Minimum essential medium) containing 10% FBS (fetal bovine serum, fetal bovine serum) (Welgene) and 25 mM HEPES (4- (2-hydroxyethyl) -1-piperazineethanesulfonic acid) Subcultured in medium.
  • FBS fetal bovine serum, fetal bovine serum
  • HEPES 4- (2-hydroxyethyl) -1-piperazineethanesulfonic acid
  • the black shaft extract extracted in Example 1 was confirmed to inhibit the growth of ACHN cells, which are kidney cancer cells. Specifically, 6.0 x 10 per well in a 96 well plate 3 The black axis dissolved in DMSO (dimethyl sulfoxide) after seeding and incubating for 24 hours in ACHN kidney cancer cells When the ethanol extract was treated at concentrations of 0 to 100 ⁇ g / ml (specifically, concentrations of 0, 3.125, 6.25, 12.5, 25, 50, and 100 ⁇ g / ml, respectively) for 48 hours, the degree of inhibition of cell growth was confirmed. (Table 1 and FIG. 1).
  • the IC 50 half maximal inhibitory concentration
  • Table 1 describes the relative cell numbers of kidney cancer cells after 48 hours according to each of the treatment rates, based on the number of survival rates of the kidney cancer cells of the control group not treated with the black axis.
  • the black shaft extract of the present invention has excellent ACHN cell killing activity, and further demonstrates the therapeutic and prophylactic activity of kidney cancer.
  • Acute toxicity test was performed using 6-week-old SPF SD rats. Two animals per group were suspended orally administered at a dose of 5 g / kg in the black shaft extract of Example 1 of the present invention in 0.5% methylcellulose solution. After administration of the test substance, mortality, clinical symptoms, and changes in body weight were observed. Hematological and hematological examinations were performed. Necropsy was performed to observe abdominal and thoracic organ abnormalities.
  • EdU assay is the same test method as BrdU assay and is an improved assay.
  • Halogenated nucleotides such as the pyrimidine analog bromodeoxyuridine (BrdU) are useful for staining DNA in living cells or tissues.
  • phase S which is doubled in the nucleus of the cell cycle and doubled in volume, BrdU is used instead of thymidine in the replicating DNA, and the amount of synthesized DNA can be confirmed by staining with BrdU antibody.
  • Reporter gene assay was performed to determine the effect of black axis on the major cellular signals that control cancer cell growth and proliferation.
  • Reporter gene assay is a test technique designed to confirm the change of the cell signal by introducing a reporter gene that can measure the change of a specific cell signal in the cell.
  • a reporter gene designed to measure a cell signal to be confirmed was transfected into cancer cells, stabilized, and black shafts were treated at each concentration. After 24 hours, the expression level of the reporter gene was compared to 100% in the group without black axis and 0% in the group without transduction.
  • Western blot testing was performed to determine the effect of black axis on signaling proteins involved in the major cellular signals that control cancer cell growth and proliferation.
  • Western blot is a test method that separates the whole protein by molecular weight, and then compares the amount of protein to be detected using the antibody of the protein to be identified.
  • the present inventors have confirmed that the renal cancer treatment effect of the black shaft extract is excellent through the above embodiment to prepare a kidney cancer therapeutic agent containing the black shaft extract as an active ingredient as follows.
  • the preparation of the following therapeutic agents can be used for the application of not only therapeutic agents but also black foods.
  • the present inventors have confirmed that the black shaft extract is excellent in the renal cancer treatment activity through the above embodiment to prepare a functional food containing it as an active ingredient as follows.
  • Chewing gum was prepared using a conventional method using the composition and content of 20% of gum base, 76.36 to 76.76% of sugar, 0.24 to 0.64% of black shaft extract, 1% of fruit flavor, and 2% of water.
  • Candy was prepared using a conventional method with the above composition and content of 50 to 60% of sugar, 39.26 to 49.66% of starch syrup, 0.24 to 0.64% of black shaft extract, and 0.1% of orange flavor.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Botany (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Nutrition Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

La présente invention concerne une utilisation inédite d'un extrait de semen Pharbitidis, dans le cadre de laquelle une composition utilisable à des fins thérapeutiques et en tant qu'aliment fonctionnel contient, en tant que principe actif, un extrait de semen Pharbitidis présentant de remarquables effets préventifs et curatifs sur le cancer du rein. L'extrait de semen Pharbitidis selon la présente invention inhibe le développement des cellules du cancer du rein et induit leur apoptose, si bien qu'il peut être utilisé de façon efficace pour traiter et prévenir le cancer du rein.
PCT/KR2012/009744 2012-11-16 2012-11-16 Composition contenant de l'extrait de semen pharbitidis utilisable pour traiter le cancer du rein et en tant qu'aliment fonctionnel Ceased WO2014077437A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
PCT/KR2012/009744 WO2014077437A1 (fr) 2012-11-16 2012-11-16 Composition contenant de l'extrait de semen pharbitidis utilisable pour traiter le cancer du rein et en tant qu'aliment fonctionnel

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/KR2012/009744 WO2014077437A1 (fr) 2012-11-16 2012-11-16 Composition contenant de l'extrait de semen pharbitidis utilisable pour traiter le cancer du rein et en tant qu'aliment fonctionnel

Publications (1)

Publication Number Publication Date
WO2014077437A1 true WO2014077437A1 (fr) 2014-05-22

Family

ID=50731340

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2012/009744 Ceased WO2014077437A1 (fr) 2012-11-16 2012-11-16 Composition contenant de l'extrait de semen pharbitidis utilisable pour traiter le cancer du rein et en tant qu'aliment fonctionnel

Country Status (1)

Country Link
WO (1) WO2014077437A1 (fr)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060264383A1 (en) * 2005-05-18 2006-11-23 Kingston David G I Morning glory-derived anticancer agents, and novel ipomoeassin compounds
KR20120092287A (ko) * 2011-02-11 2012-08-21 주식회사한국전통의학연구소 흑축 추출물을 유효성분으로 함유하는 뇌암의 예방 및 치료용 약학적 조성물
KR20120122405A (ko) * 2011-04-29 2012-11-07 주식회사한국전통의학연구소 백축 추출물을 포함하는 신장암 치료용 조성물 및 화장료 조성물

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060264383A1 (en) * 2005-05-18 2006-11-23 Kingston David G I Morning glory-derived anticancer agents, and novel ipomoeassin compounds
KR20120092287A (ko) * 2011-02-11 2012-08-21 주식회사한국전통의학연구소 흑축 추출물을 유효성분으로 함유하는 뇌암의 예방 및 치료용 약학적 조성물
KR20120122405A (ko) * 2011-04-29 2012-11-07 주식회사한국전통의학연구소 백축 추출물을 포함하는 신장암 치료용 조성물 및 화장료 조성물

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
LEE ET AL: "SCREENING FOR ANTITUMOR EFFICACY FROM THE WILD PLANTS IN KOREA", KOREAN JOURNAL PF PLANTS RESOURCES, vol. 5, no. 2, 1992, pages 85 - 93 *
PARK ET AL: "SELECTION OF ORIENTAL MEDICINAL PLANTS FOR SCREENING OF ANTICAMCER AGENTS", KOREAN JOURNAL BIOTECHNOLOGY AND BIOENGINEERING, vol. 22, no. 3, 2007, pages 139 - 145 *

Similar Documents

Publication Publication Date Title
WO2012134169A2 (fr) Composition pour le traitement du cancer du poumon et aliment fonctionnel contenant un extrait de semence de gleditsiae
WO2012134252A2 (fr) Composition pour le traitement du cancer du rein et aliment fonctionnel contenant un extrait de semence de cannabis
KR20130022394A (ko) 정향수피 추출물을 포함하는 췌장암 치료용 조성물 및 건강 기능성 식품
KR102054437B1 (ko) 조각인 추출물을 포함하는 신장암 치료용 조성물 및 건강 기능성 식품
WO2012134250A2 (fr) Composition pour le traitement du cancer du rein et composition pour produits cosmétiques contenant un extrait de rhizome de nardostachys
KR20120122410A (ko) 목향 추출물을 포함하는 신장암 치료용 조성물 및 건강 기능성 식품
WO2014077437A1 (fr) Composition contenant de l'extrait de semen pharbitidis utilisable pour traiter le cancer du rein et en tant qu'aliment fonctionnel
KR20120122405A (ko) 백축 추출물을 포함하는 신장암 치료용 조성물 및 화장료 조성물
WO2014069692A1 (fr) Composition pour traiter le cancer rénal et aliment santé fonctionnel contenant un extrait d'inula britannica var. chinensis
WO2013147340A1 (fr) Composition et complément alimentaire pour traiter le cancer du poumon, contenant un extrait d'encens
WO2014077433A1 (fr) Composition contenant de l'extrait de semen gleditsiae utilisable pour traiter le cancer du rein et en tant qu'aliment fonctionnel
WO2012134167A2 (fr) Composition pour le traitement du cancer du poumon et aliment fonctionnel contenant un extrait d'eriobotriae folium
WO2014077432A1 (fr) Composition contenant de l'extrait de radix rubiae utilisable pour traiter le cancer du rein et à des fins cosmétiques
KR101385658B1 (ko) 익지인 추출물을 포함하는 전립선암 치료용 조성물 및 기능성 식품
WO2014069695A1 (fr) Composition pour traiter le cancer du pancréas et aliment santé fonctionnel contenant un extrait de boswellia
KR20120111121A (ko) 구절초 추출물을 포함하는 신장암 치료용 조성물 및 건강 기능성 식품
KR20130023172A (ko) 흑축 추출물을 포함하는 신장암 치료용 조성물 및 건강 기능성 식품
WO2014077438A1 (fr) Composition contenant de l'extrait de semen pharbitidis utilisable pour traiter le cancer du pancréas et en tant qu'aliment fonctionnel
WO2014069686A1 (fr) Composition pour traiter le cancer rénal et aliment santé fonctionnel contenant un extrait de racine de trichosanthis
KR20120122404A (ko) 괄루근 추출물을 포함하는 신장암 치료용 조성물 및 건강 기능성 식품
KR20130023176A (ko) 필발 추출물을 포함하는 췌장암 치료용 조성물 및 건강 기능성 식품
KR20130023174A (ko) 지실 추출물을 포함하는 췌장암 치료용 조성물 및 건강 기능성 식품
WO2014069689A1 (fr) Composition pour traiter le cancer rénal et aliment santé fonctionnel contenant un extrait de racine de saussurae
KR20120122413A (ko) 선복화 추출물을 포함하는 신장암 치료용 조성물 및 건강 기능성 식품
WO2014069691A1 (fr) Composition pour traiter le cancer rénal et aliment santé fonctionnel contenant un extrait de cnidium monnieri

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12888295

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 12888295

Country of ref document: EP

Kind code of ref document: A1